Clinical Trials Logo

Relapsed/Refractory AML clinical trials

View clinical trials related to Relapsed/Refractory AML.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04623944 Active, not recruiting - MDS Clinical Trials

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Start date: September 21, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.